Technical Analysis for BYSI - BeyondSpring, Inc.

Grade Last Price % Change Price Change
grade B 17.56 -2.93% -0.53
BYSI closed down 2.93 percent on Wednesday, February 19, 2020, on 88 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical BYSI trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Touch Strength 0.00%
180 Bullish Setup Bullish Swing Setup -2.93%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.06%
Calm After Storm Range Contraction 0.06%
Outside Day Range Expansion 0.06%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 4.03%
Calm After Storm Range Contraction 4.03%
NR7 Range Contraction 4.03%
Inside Day Range Contraction 4.03%
200 DMA Support Bullish 4.21%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.
Chemistry Biopharmaceutical Cancer Clinical Medicine Chemotherapy Cancer Treatments Organic Chemistry Antineoplastic Drugs Cancer Therapies Advanced Non Small Cell Lung Cancer Buparlisib Docetaxel Imidazoles Neutropenia

Is BYSI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 24.8
52 Week Low 11.26
Average Volume 61,880
200-Day Moving Average 16.64
50-Day Moving Average 16.08
20-Day Moving Average 16.53
10-Day Moving Average 17.24
Average True Range 1.06
ADX 28.96
+DI 27.64
-DI 10.62
Chandelier Exit (Long, 3 ATRs ) 15.57
Chandelier Exit (Short, 3 ATRs ) 17.74
Upper Bollinger Band 18.59
Lower Bollinger Band 14.48
Percent B (%b) 0.75
BandWidth 24.87
MACD Line 0.40
MACD Signal Line 0.31
MACD Histogram 0.0847
Fundamentals Value
Market Cap 401.14 Million
Num Shares 22.8 Million
EPS -3.71
Price-to-Earnings (P/E) Ratio -4.73
Price-to-Sales 0.00
Price-to-Book 16.76
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.66
Resistance 3 (R3) 19.82 19.29 19.31
Resistance 2 (R2) 19.29 18.75 19.21 19.19
Resistance 1 (R1) 18.42 18.42 18.16 18.26 19.08
Pivot Point 17.89 17.89 17.75 17.81 17.89
Support 1 (S1) 17.02 17.35 16.76 16.86 16.04
Support 2 (S2) 16.49 17.02 16.41 15.93
Support 3 (S3) 15.62 16.49 15.81
Support 4 (S4) 15.46